Keyphrases
Nivolumab
100%
Non-small Cell Lung Cancer Patients
100%
CNS Metastases
100%
Intracranial Response
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Non-small Cell Lung Cancer (NSCLC)
33%
Leptomeningeal Carcinomatosis
33%
Magnetic Resonance Imaging
16%
Corticosteroids
16%
Immune Checkpoint Inhibitors
16%
Adverse Events
16%
Treatment-related
16%
Central Nervous System
16%
Safety Profile
16%
Brain Metastases
16%
Systemic Therapy
16%
Second-line Treatment
16%
Targeted Treatment
16%
Time Response
16%
Partial Response
16%
Localized Treatment
16%
Neurocognitive Impairment
16%
Local Therapy
16%
Central Nervous System Activity
16%
Start of Treatment
16%
Systemic Response
16%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
16%
Radiological Criteria
16%
Intracranial Metastases
16%
Medicine and Dentistry
Nivolumab
100%
Non Small Cell Lung Cancer
100%
Central Nervous System Metastasis
100%
Central Nervous System
33%
Meningeal Carcinomatosis
33%
Immune Checkpoint Inhibitor
16%
Adverse Event
16%
Magnetic Resonance Imaging
16%
Metastatic Carcinoma
16%
Brain Metastasis
16%
Systemic Therapy
16%
Local Therapy
16%
Treatment of Non-Small Cell Lung Cancer
16%